According to a new study, patients with Type 2 diabetes may be aspirin resistant, which means that the standard dose given to protect against heart attack and stroke may not work for them.

The study analyzed aspirin’s clotting effects using an analysis of 142 men with Type 2 diabetes, which is the most common form of the disease.

Researchers measured aspirin’s effect on a chemical that is involved in the blood-clotting process, and found that more than half of the participants — 53 percent — were aspirin resistant.

Earlier studies had indicated some degree of aspirin resistance in people with diabetes, but this study suggested that the process may be widespread, said lead author Subhashini Yaturo, M.D., of the Stratton VA Medical Center in Albany, N.Y.

It also demonstrates that “the standard baby aspirin dose (81 mg) may not be adequate for subjects with diabetes for cardiovascular protection.”

More research is needed to identify people with aspirin resistance, so anticlotting drug regimens can be tailored for them, added Dr. Yaturo.